Kimberly-Clark Closes $40B Kenvue Deal, Doubling Down on Consumer Health
KMB sits 17% above its 52-week low of $92.42 on elevated volume (2.3× avg).
Summary
Kimberly-Clark closed its $40 billion acquisition of Kenvue, the deal that turns the tissue-and-diaper maker into a combined consumer health and personal care company, and reiterated anticipated run-rate synergies of $2.1 billion. The path was cleared over the past three months: EU approval on October 13, Australian ACCC clearance in September with a required divestiture of Kenvue's Carefree and Stayfree brands, and 90.2% early tender participation in the $7 billion Kenvue note exchange. Financing is now in place — KMB priced and closed $4.9 billion of senior notes in five tranches on October 20 and 29 to fund the cash portion. The integration is the story from here: KMB pre-announced Q3 net sales of $4.13 billion, down 0.4% with organic down 1.3%, and cut its full-year outlook in August, so the combined company has to show it can stabilize the base business while absorbing Kenvue. Note that President and COO Russell Torres departs effective today, the same day the deal closes.
At the time of this announcement, KMB was trading at $108.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $35.9B. The 52-week trading range was $92.42 to $123.09. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.